In agreement with our previous findings,22 ST6GAL1 serum levels were 7.3-fold higher in men diagnosed with prostate cancer relative to men without prostate cancer (n = 240, unpaired t test, p < 0.0001) (Fig. 3a). Here, ST6GAL1 is linked to prostate carcinoma.